SK bioscience

본문바로가기

KOR ENG

sitemap

PR

SK bioscience company news updates

Media Zoom

SK Bioscience begins ´globalization´ push, paying $244M for majority stake in contract manufacturer IDT Biologika

2024.06.07
SK bioscience, Sanofi ink contract for five types of vaccines

2024.03.27
SK bioscience devises new business strategy for post-pandemic era

2024.03.25
SK bioscience and IVI Announce 2024 Park MahnHoon Award Winners

2024.03.15
Novavax´s updated COVID-19 vaccine to help provide wider array of choices

2023.12.24
[From the Scene] SK bioscience rolls out Korea´s first cell-based flu vaccine

2023.08.23
SK bioscience breaks ground on Songdo R&PD Center

2023.06.22
[Herald Interview] Global teamwork key for future pandemic response: AstraZeneca co-developer

2023.05.01
SK bioscience to invest big in vaccines, CDMO over next 5 years

2023.04.28
SK bioscience to invest $1.8 bil. by 2027 to become top-tier bio firm

2023.04.28
SK bioscience to invest US$1.79 bln; eyes contract manufacturing deal

2023.04.28
SK Bioscience to invest W2.4tr by 2027

2023.04.28